Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
Products
Automate
Trackers
Innovation Services
About Index
Index
By TNW
Log in
Register
Sigilon Therapeutics
3151
Sigilon Therapeutics
Technology
Biotechnology
Health Care
Medical
Therapeutics
Immune-privileged living therapeutics
Suggest edits
Type
B2c
Raised
$80.3M
Follow us
Also headquartered in Cambridge
MIT
Raspberry Pi
ARM
Xconomy
Biogen
Money Mover
HubSpot
Formlabs
Akamai
General Catalyst
Companies in the same industry
eTheRNA Immunotherapies
Clearside BioMedical, Inc.
Mersana Therapeutics
Brainvectis
Immunic AG
Methylation Sciences
Arsia Therapeutics
Vividion Therapeutics
Quentis Therapeutics
Eidos Therapeutics
Alexa global traffic share
Twitter followers
Overview
Funding
2
Add info
Latest funding
$80,300,000
Venture capital (Series B) - 2020
Eli Lilly and Company
Flagship Pioneering
Canada Pension Plan Investment Board (CPP Investments)
+1
Undisclosed amount
Undisclosed funding - 2018
Eli Lilly and Company
Team Size
1–10
Employees
I work here
Location
Cambridge
,
United States
Headquarters
Explore Cambridge
$80,300,000
Venture capital (Series B)
FinSMEs
Sigilon Therapeutics Raises $80.3M in Series B Financing
Undisclosed funding
FinSMEs
Sigilon Therapeutics Receives Investment from Eli Lilly and Company
Health
Funding
Software development